1 | interventional | 2,063 |
2 | large-scale | 2,053 |
3 | high-quality | 1,904 |
4 | pragmatic | 1,535 |
5 | well-designed | 1,336 |
6 | nonrandomized | 928 |
7 | head-to-head | 800 |
8 | non-randomized | 746 |
9 | non-randomised | 592 |
10 | single-site | 253 |
11 | well-conducted | 231 |
12 | n-of-1 | 169 |
13 | small-scale | 166 |
14 | good-quality | 160 |
15 | unconfounded | 131 |
16 | treat-to-target | 98 |
17 | larger-scale | 90 |
18 | industry-sponsored | 81 |
19 | non-controlled | 75 |
20 | relapse-prevention | 70 |
21 | higher-quality | 63 |
22 | non-commercial | 61 |
23 | self-controlled | 61 |
24 | non-experimental | 54 |
25 | poor-quality | 53 |
26 | multi-arm | 52 |
27 | noncontrolled | 50 |
28 | biomarker-based | 38 |
29 | industry-funded | 37 |
30 | nonrandomised | 37 |
31 | large-sample | 33 |
32 | noninterventional | 33 |
33 | outcome-based | 33 |
34 | well-powered | 33 |
35 | fair-quality | 32 |
36 | adequately-powered | 30 |
37 | multiregional | 30 |
38 | outlying | 30 |
39 | hypothesis-driven | 26 |
40 | single-patient | 25 |
41 | post-approval | 24 |
42 | pre-test/post-test | 24 |
43 | better-designed | 20 |
44 | well-done | 20 |
45 | industry-supported | 19 |
46 | level-i | 17 |
47 | non-placebo-controlled | 17 |
48 | phase-i | 17 |
49 | well-constructed | 17 |
50 | secondary-prevention | 16 |
51 | well-reported | 16 |
52 | well-performed | 15 |
53 | biomarker-driven | 14 |
54 | nih-sponsored | 13 |
55 | patient-preference | 13 |
56 | dmoad | 12 |
57 | large-scaled | 12 |
58 | late-breaking | 12 |
59 | multi-central | 12 |
60 | premarketing | 12 |
61 | better-quality | 11 |
62 | lower-quality | 11 |
63 | multi-armed | 11 |
64 | intervention-based | 10 |
65 | well-executed | 10 |
66 | industry-initiated | 9 |
67 | effect-controlled | 8 |
68 | fellow-eye | 8 |
69 | level-ii | 8 |
70 | outcomes-based | 8 |
71 | disease-modification | 7 |
72 | pre-licensure | 7 |
73 | single-armed | 7 |
74 | adequately-sized | 6 |
75 | better-controlled | 6 |
76 | company-sponsored | 6 |
77 | hoxb9 | 6 |
78 | jasp/er | 6 |
79 | vt-np | 6 |
80 | actively-controlled | 5 |
81 | cancer-prevention | 5 |
82 | child-only | 5 |
83 | limited-quality | 5 |
84 | multiple-arm | 5 |
85 | uk-led | 5 |
86 | activity-abolishing | 4 |
87 | advanced-disease | 4 |
88 | best-designed | 4 |
89 | combination-drug | 4 |
90 | df/bp | 4 |
91 | dose-control | 4 |
92 | non-double-blinded | 4 |
93 | nonregistered | 4 |
94 | small-scaled | 4 |
95 | vendor-supported | 4 |
96 | ada-deficiency | 3 |
97 | best-quality | 3 |
98 | cam-based | 3 |
99 | effectiveness-oriented | 3 |
100 | genome-specific | 3 |
101 | isophane-based | 3 |
102 | odds-ratio-based | 3 |
103 | pegda/ha | 3 |
104 | prevention-based | 3 |
105 | single-assessment | 3 |
106 | single-intervention | 3 |
107 | sponsor-initiated | 3 |
108 | 12-site | 2 |
109 | 17,591 | 2 |
110 | 3,404 | 2 |
111 | 3-arms | 2 |
112 | 5,472 | 2 |
113 | activity-reducing | 2 |
114 | biologic-second-line | 2 |
115 | cmj101c | 2 |
116 | corporate-sponsored | 2 |
117 | effectiveness.the | 2 |
118 | good-sized | 2 |
119 | neurodegeneration-related | 2 |
120 | nonparameteric | 2 |
121 | randomization/blinding | 2 |
122 | task-switch | 2 |
123 | treatment.four | 2 |
124 | treatment.no | 2 |
125 | trichiatic | 2 |
126 | 12,627 | 1 |
127 | 21,220 | 1 |
128 | 22,616 | 1 |
129 | 34,014 | 1 |
130 | 46.4-km | 1 |
131 | 551,358 | 1 |
132 | 553,084 | 1 |
133 | 736,996 | 1 |
134 | 9,290 | 1 |
135 | adjuvant-therapy | 1 |
136 | agency-funded | 1 |
137 | analyses.two | 1 |
138 | autapomorphies | 1 |
139 | bioabstracts | 1 |
140 | cefadroxil-controlled | 1 |
141 | cer-type | 1 |
142 | clinical-control | 1 |
143 | co-publishing | 1 |
144 | drugs.future | 1 |
145 | elligible | 1 |
146 | evidence-generating | 1 |
147 | evidence-no | 1 |
148 | exobiology | 1 |
149 | filled-with-catalyst | 1 |
150 | gbc-specific | 1 |
151 | geriatric-type | 1 |
152 | ggh-associated | 1 |
153 | group-group | 1 |
154 | haplotype-tag | 1 |
155 | high-methodological-quality | 1 |
156 | implementation-profiling | 1 |
157 | investigation.in | 1 |
158 | large-sample-size | 1 |
159 | linical | 1 |
160 | lrtis.three | 1 |
161 | micronutrient-supplementation | 1 |
162 | mildly-oxidized | 1 |
163 | multicentre/international | 1 |
164 | multicentric/international | 1 |
165 | non-genotyped | 1 |
166 | nuance | 1 |
167 | omics-driven | 1 |
168 | participants.five | 1 |
169 | placebo-referenced | 1 |
170 | pn-treated | 1 |
171 | priori-selected | 1 |
172 | probe-designed | 1 |
173 | quality-commissioned | 1 |
174 | radiology/endovascular | 1 |
175 | research.the | 1 |
176 | review.four | 1 |
177 | reviewer.twenty-nine | 1 |
178 | sedation.four | 1 |
179 | studies,106 | 1 |
180 | studies.two | 1 |
181 | suitably-designed | 1 |
182 | surgery.three | 1 |
183 | the15 | 1 |
184 | uphill-cycling | 1 |
185 | use.fifteen | 1 |
186 | use.ten | 1 |
187 | wc-associated | 1 |
188 | work.molecular | 1 |
1 | 12,627 | 1 |
2 | 12-site | 2 |
3 | 17,591 | 2 |
4 | 21,220 | 1 |
5 | 22,616 | 1 |
6 | 3,404 | 2 |
7 | 3-arms | 2 |
8 | 34,014 | 1 |
9 | 46.4-km | 1 |
10 | 5,472 | 2 |
11 | 551,358 | 1 |
12 | 553,084 | 1 |
13 | 736,996 | 1 |
14 | 9,290 | 1 |
15 | actively-controlled | 5 |
16 | activity-abolishing | 4 |
17 | activity-reducing | 2 |
18 | ada-deficiency | 3 |
19 | adequately-powered | 30 |
20 | adequately-sized | 6 |
21 | adjuvant-therapy | 1 |
22 | advanced-disease | 4 |
23 | agency-funded | 1 |
24 | analyses.two | 1 |
25 | autapomorphies | 1 |
26 | best-designed | 4 |
27 | best-quality | 3 |
28 | better-controlled | 6 |
29 | better-designed | 20 |
30 | better-quality | 11 |
31 | bioabstracts | 1 |
32 | biologic-second-line | 2 |
33 | biomarker-based | 38 |
34 | biomarker-driven | 14 |
35 | cam-based | 3 |
36 | cancer-prevention | 5 |
37 | cefadroxil-controlled | 1 |
38 | cer-type | 1 |
39 | child-only | 5 |
40 | clinical-control | 1 |
41 | cmj101c | 2 |
42 | co-publishing | 1 |
43 | combination-drug | 4 |
44 | company-sponsored | 6 |
45 | corporate-sponsored | 2 |
46 | df/bp | 4 |
47 | disease-modification | 7 |
48 | dmoad | 12 |
49 | dose-control | 4 |
50 | drugs.future | 1 |
51 | effect-controlled | 8 |
52 | effectiveness-oriented | 3 |
53 | effectiveness.the | 2 |
54 | elligible | 1 |
55 | evidence-generating | 1 |
56 | evidence-no | 1 |
57 | exobiology | 1 |
58 | fair-quality | 32 |
59 | fellow-eye | 8 |
60 | filled-with-catalyst | 1 |
61 | gbc-specific | 1 |
62 | genome-specific | 3 |
63 | geriatric-type | 1 |
64 | ggh-associated | 1 |
65 | good-quality | 160 |
66 | good-sized | 2 |
67 | group-group | 1 |
68 | haplotype-tag | 1 |
69 | head-to-head | 800 |
70 | high-methodological-quality | 1 |
71 | high-quality | 1,904 |
72 | higher-quality | 63 |
73 | hoxb9 | 6 |
74 | hypothesis-driven | 26 |
75 | implementation-profiling | 1 |
76 | industry-funded | 37 |
77 | industry-initiated | 9 |
78 | industry-sponsored | 81 |
79 | industry-supported | 19 |
80 | intervention-based | 10 |
81 | interventional | 2,063 |
82 | investigation.in | 1 |
83 | isophane-based | 3 |
84 | jasp/er | 6 |
85 | large-sample | 33 |
86 | large-sample-size | 1 |
87 | large-scale | 2,053 |
88 | large-scaled | 12 |
89 | larger-scale | 90 |
90 | late-breaking | 12 |
91 | level-i | 17 |
92 | level-ii | 8 |
93 | limited-quality | 5 |
94 | linical | 1 |
95 | lower-quality | 11 |
96 | lrtis.three | 1 |
97 | micronutrient-supplementation | 1 |
98 | mildly-oxidized | 1 |
99 | multi-arm | 52 |
100 | multi-armed | 11 |
101 | multi-central | 12 |
102 | multicentre/international | 1 |
103 | multicentric/international | 1 |
104 | multiple-arm | 5 |
105 | multiregional | 30 |
106 | n-of-1 | 169 |
107 | neurodegeneration-related | 2 |
108 | nih-sponsored | 13 |
109 | non-commercial | 61 |
110 | non-controlled | 75 |
111 | non-double-blinded | 4 |
112 | non-experimental | 54 |
113 | non-genotyped | 1 |
114 | non-placebo-controlled | 17 |
115 | non-randomised | 592 |
116 | non-randomized | 746 |
117 | noncontrolled | 50 |
118 | noninterventional | 33 |
119 | nonparameteric | 2 |
120 | nonrandomised | 37 |
121 | nonrandomized | 928 |
122 | nonregistered | 4 |
123 | nuance | 1 |
124 | odds-ratio-based | 3 |
125 | omics-driven | 1 |
126 | outcome-based | 33 |
127 | outcomes-based | 8 |
128 | outlying | 30 |
129 | participants.five | 1 |
130 | patient-preference | 13 |
131 | pegda/ha | 3 |
132 | phase-i | 17 |
133 | placebo-referenced | 1 |
134 | pn-treated | 1 |
135 | poor-quality | 53 |
136 | post-approval | 24 |
137 | pragmatic | 1,535 |
138 | pre-licensure | 7 |
139 | pre-test/post-test | 24 |
140 | premarketing | 12 |
141 | prevention-based | 3 |
142 | priori-selected | 1 |
143 | probe-designed | 1 |
144 | quality-commissioned | 1 |
145 | radiology/endovascular | 1 |
146 | randomization/blinding | 2 |
147 | relapse-prevention | 70 |
148 | research.the | 1 |
149 | review.four | 1 |
150 | reviewer.twenty-nine | 1 |
151 | secondary-prevention | 16 |
152 | sedation.four | 1 |
153 | self-controlled | 61 |
154 | single-armed | 7 |
155 | single-assessment | 3 |
156 | single-intervention | 3 |
157 | single-patient | 25 |
158 | single-site | 253 |
159 | small-scale | 166 |
160 | small-scaled | 4 |
161 | sponsor-initiated | 3 |
162 | studies,106 | 1 |
163 | studies.two | 1 |
164 | suitably-designed | 1 |
165 | surgery.three | 1 |
166 | task-switch | 2 |
167 | the15 | 1 |
168 | treat-to-target | 98 |
169 | treatment.four | 2 |
170 | treatment.no | 2 |
171 | trichiatic | 2 |
172 | uk-led | 5 |
173 | unconfounded | 131 |
174 | uphill-cycling | 1 |
175 | use.fifteen | 1 |
176 | use.ten | 1 |
177 | vendor-supported | 4 |
178 | vt-np | 6 |
179 | wc-associated | 1 |
180 | well-conducted | 231 |
181 | well-constructed | 17 |
182 | well-designed | 1,336 |
183 | well-done | 20 |
184 | well-executed | 10 |
185 | well-performed | 15 |
186 | well-powered | 33 |
187 | well-reported | 16 |
188 | work.molecular | 1 |
1 | 21,220 | 1 |
2 | 9,290 | 1 |
3 | n-of-1 | 169 |
4 | 17,591 | 2 |
5 | 5,472 | 2 |
6 | 3,404 | 2 |
7 | 34,014 | 1 |
8 | 553,084 | 1 |
9 | the15 | 1 |
10 | studies,106 | 1 |
11 | 22,616 | 1 |
12 | 736,996 | 1 |
13 | 12,627 | 1 |
14 | 551,358 | 1 |
15 | hoxb9 | 6 |
16 | pegda/ha | 3 |
17 | cmj101c | 2 |
18 | gbc-specific | 1 |
19 | genome-specific | 3 |
20 | nonparameteric | 2 |
21 | trichiatic | 2 |
22 | pragmatic | 1,535 |
23 | head-to-head | 800 |
24 | dmoad | 12 |
25 | placebo-referenced | 1 |
26 | non-double-blinded | 4 |
27 | agency-funded | 1 |
28 | industry-funded | 37 |
29 | unconfounded | 131 |
30 | uk-led | 5 |
31 | large-scaled | 12 |
32 | small-scaled | 4 |
33 | self-controlled | 61 |
34 | cefadroxil-controlled | 1 |
35 | non-controlled | 75 |
36 | non-placebo-controlled | 17 |
37 | better-controlled | 6 |
38 | effect-controlled | 8 |
39 | actively-controlled | 5 |
40 | noncontrolled | 50 |
41 | single-armed | 7 |
42 | multi-armed | 11 |
43 | well-performed | 15 |
44 | probe-designed | 1 |
45 | well-designed | 1,336 |
46 | better-designed | 20 |
47 | best-designed | 4 |
48 | suitably-designed | 1 |
49 | quality-commissioned | 1 |
50 | non-genotyped | 1 |
51 | nonregistered | 4 |
52 | well-powered | 33 |
53 | adequately-powered | 30 |
54 | corporate-sponsored | 2 |
55 | nih-sponsored | 13 |
56 | company-sponsored | 6 |
57 | industry-sponsored | 81 |
58 | outcome-based | 33 |
59 | isophane-based | 3 |
60 | cam-based | 3 |
61 | prevention-based | 3 |
62 | intervention-based | 10 |
63 | odds-ratio-based | 3 |
64 | biomarker-based | 38 |
65 | outcomes-based | 8 |
66 | non-randomised | 592 |
67 | nonrandomised | 37 |
68 | pn-treated | 1 |
69 | wc-associated | 1 |
70 | ggh-associated | 1 |
71 | sponsor-initiated | 3 |
72 | industry-initiated | 9 |
73 | neurodegeneration-related | 2 |
74 | priori-selected | 1 |
75 | well-conducted | 231 |
76 | well-constructed | 17 |
77 | effectiveness-oriented | 3 |
78 | well-reported | 16 |
79 | vendor-supported | 4 |
80 | industry-supported | 19 |
81 | well-executed | 10 |
82 | mildly-oxidized | 1 |
83 | non-randomized | 746 |
84 | nonrandomized | 928 |
85 | good-sized | 2 |
86 | adequately-sized | 6 |
87 | nuance | 1 |
88 | patient-preference | 13 |
89 | lrtis.three | 1 |
90 | surgery.three | 1 |
91 | research.the | 1 |
92 | effectiveness.the | 2 |
93 | large-scale | 2,053 |
94 | small-scale | 166 |
95 | larger-scale | 90 |
96 | elligible | 1 |
97 | large-sample | 33 |
98 | biologic-second-line | 2 |
99 | reviewer.twenty-nine | 1 |
100 | well-done | 20 |
101 | geriatric-type | 1 |
102 | cer-type | 1 |
103 | pre-licensure | 7 |
104 | drugs.future | 1 |
105 | advanced-disease | 4 |
106 | 12-site | 2 |
107 | single-site | 253 |
108 | participants.five | 1 |
109 | fellow-eye | 8 |
110 | large-sample-size | 1 |
111 | haplotype-tag | 1 |
112 | activity-reducing | 2 |
113 | randomization/blinding | 2 |
114 | co-publishing | 1 |
115 | activity-abolishing | 4 |
116 | late-breaking | 12 |
117 | uphill-cycling | 1 |
118 | implementation-profiling | 1 |
119 | evidence-generating | 1 |
120 | premarketing | 12 |
121 | outlying | 30 |
122 | combination-drug | 4 |
123 | task-switch | 2 |
124 | phase-i | 17 |
125 | level-i | 17 |
126 | level-ii | 8 |
127 | linical | 1 |
128 | non-commercial | 61 |
129 | multiregional | 30 |
130 | multicentric/international | 1 |
131 | multicentre/international | 1 |
132 | interventional | 2,063 |
133 | noninterventional | 33 |
134 | multi-central | 12 |
135 | non-experimental | 54 |
136 | post-approval | 24 |
137 | dose-control | 4 |
138 | clinical-control | 1 |
139 | 46.4-km | 1 |
140 | multiple-arm | 5 |
141 | multi-arm | 52 |
142 | use.fifteen | 1 |
143 | use.ten | 1 |
144 | biomarker-driven | 14 |
145 | omics-driven | 1 |
146 | hypothesis-driven | 26 |
147 | investigation.in | 1 |
148 | disease-modification | 7 |
149 | micronutrient-supplementation | 1 |
150 | relapse-prevention | 70 |
151 | cancer-prevention | 5 |
152 | secondary-prevention | 16 |
153 | single-intervention | 3 |
154 | evidence-no | 1 |
155 | treatment.no | 2 |
156 | studies.two | 1 |
157 | analyses.two | 1 |
158 | df/bp | 4 |
159 | vt-np | 6 |
160 | group-group | 1 |
161 | work.molecular | 1 |
162 | radiology/endovascular | 1 |
163 | jasp/er | 6 |
164 | sedation.four | 1 |
165 | treatment.four | 2 |
166 | review.four | 1 |
167 | autapomorphies | 1 |
168 | 3-arms | 2 |
169 | bioabstracts | 1 |
170 | treat-to-target | 98 |
171 | single-patient | 25 |
172 | single-assessment | 3 |
173 | pre-test/post-test | 24 |
174 | filled-with-catalyst | 1 |
175 | ada-deficiency | 3 |
176 | exobiology | 1 |
177 | child-only | 5 |
178 | adjuvant-therapy | 1 |
179 | limited-quality | 5 |
180 | good-quality | 160 |
181 | high-quality | 1,904 |
182 | high-methodological-quality | 1 |
183 | higher-quality | 63 |
184 | better-quality | 11 |
185 | lower-quality | 11 |
186 | fair-quality | 32 |
187 | poor-quality | 53 |
188 | best-quality | 3 |